Doç. Dr. Mesut Ayer
Is this your profile? Claim it and verify your details.
Claim profilePerson ↔ Disease
Which diseases does this doctor work on?
-
Myelodysplastic Syndromes 3 publicationsSource: OpenAlex / PubMed MeSHView publications
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 publications
- Purpura, Thrombocytopenic, Idiopathic 3 publications
- Multiple Myeloma 3 publications
- Lymphoma, Large B-Cell, Diffuse 2 publications
- Thrombocythemia, Essential 2 publications
- Lymphoma, Non-Hodgkin 2 publications
Trust
Where does this information come from?
The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.
- SpecialtyHaematologysaglik.gov.trFrom source
- InstitutionBaşakşehir Çam ve Sakura Şehir Hastanesisaglik.gov.trFrom source
- Area of workMyelodysplastic SyndromesExtracted from 3 publications · Model version —From source
- Publications87 publicationsOpenAlex, ORCIDFrom source
- ORCID0000-0003-1977-0104ORCIDFrom source
- Last synchronised5 November 2026 10:36https://camsakurasehir.saglik.gov.tr/TR-1290328/gorev-yapan-hekimlerimiz.html#mesut-ayersaglik.gov.tr
Scientific work
Publications on Myelodysplastic Syndromes
-
Real-world effectiveness and safety of fixed-duration frontline venetoclax–obinutuzumab for chronic lymphocytic leukemia: A nationwide multicenter retrospective cohort study
Leukemia Research, 2026
DOI 10.1016/j.leukres.2026.108342 PMID 42933070 Source: OpenAlex
-
Is Baseline PET/CT-Derived Metabolic Tumor Burden Associated with Treatment Response and Survival in Hodgkin Lymphoma?
Journal of Clinical Medicine, 2026
DOI 10.3390/jcm15176686 PMID 42739691 Open-access full textSource: ORCID
-
Comparative Prognostic Performance of Nutritional Indices in Acute Myeloid Leukemia
Journal of Clinical Medicine, 2026
DOI 10.3390/jcm15166179 PMID 42652583 Open-access full textSource: ORCID
-
Therapeutic Plasma Exchange Using Membrane Plasma Separation Across a Broad Spectrum of Indications: An Eight-Year Single-Center Retrospective Cohort Study
International Journal of General Medicine, 2026
DOI 10.2147/ijgm.s625354 PMID 42670524 Open-access full textSource: ORCID
-
Comparative Prognostic Performance of Nutritional and Inflammatory Indices in Diffuse Large B-Cell Lymphoma
Journal of Clinical Medicine, 2026
DOI 10.3390/jcm15124703 PMID 42355871 Open-access full textSource: ORCID
-
Comparative Prognostic Value of the Durie–Salmon, ISS, and mSMART Staging Systems in Multiple Myeloma
Eurasian Journal of Medical Advances, 2026
DOI 10.14744/ejma.268062 Open-access full textSource: ORCID
-
NONINVASIVE EVALUATION OF CHORIORETINAL AND PERIPAPILLARY MICROVASCULAR ALTERATIONS IN ESSENTIAL THROMBOCYTHEMIA
Retina, 2026
DOI 10.1097/iae.0000000000004757 PMID 41468588 Source: ORCID
-
Quantitative Assessment of Metabolic Tumor Heterogeneity on Baseline [18F] FDG PET/CT Predicts Prognosis in Hodgkin Lymphoma
Research Square, 2026
DOI 10.21203/rs.3.rs-10749019/v1 Open-access full textSource: ORCID
-
Publication Only
HemaSphere, 2026
DOI 10.1002/hem3.70421 Open-access full textSource: OpenAlex
-
Prognostic Value of Baseline ¹⁸F-FDG PET/CT Metabolic Tumor Burden in Multiple Myeloma
Research Square, 2026
DOI 10.21203/rs.3.rs-11025606/v1 Open-access full textSource: OpenAlex